1xbet 카지노 Pharmaceutical Co., Ltd.

1xbet 카지노 Pharmaceutical Co., Ltd. (1xbet 카지노); its subsidiary 1xbet 카지노 America Pharmaceutical, Inc.; and Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck A/S in Denmark, announce that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI^®(brexpiprazole) 1xbet 카지노 the treatment of schizophrenia in pediatric patients 13 to 17 years of age.

The FDA previously granted Priority Review 1xbet 카지노 the sNDA, a designation 1xbet 카지노 a drug application that, if approved, would represent a significant improvement in the safety and/or effectiveness of the treatment, diagnosis, or prevention of a serious medical condition. REXULTI was approved in the U.S. in 2015 1xbet 카지노 the treatment of schizophrenia in adults and 1xbet 카지노 adjunctive treatment of major depressive disorder in adults.

About Rexulti/Rxulti (brexpiprazole)

Brexpiprazole was discovered by 1xbet 카지노 and is being co-developed by 1xbet 카지노 and Lundbeck. The mechanism of action for brexpiprazole is not fully understood. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT_1Aand dopam1xbet 카지노e D₂receptors, and antagonist activity at seroton1xbet 카지노 5-HT_2Areceptors. Brexpiprazole exhibits high affinity (sub-nanomolar) 1xbet 카지노 these receptors as well as 1xbet 카지노 noradrenaline alpha1B/2C receptors. Depending on the market, brexpiprazole's brand name is Rexulti or Rxulti.